Muromonab-CD3

Muromonab-CD3 (trade name Orthoclone OKT3) is a medication used in the prevention and treatment of acute transplant rejection. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.

Mechanism of action

Muromonab-CD3 works by binding to the CD3 receptor on the surface of T cells. This binding triggers a series of events that ultimately leads to the destruction of the T cell. This reduces the number of T cells available to mount an immune response, thereby reducing the risk of transplant rejection.

Uses

Muromonab-CD3 is primarily used in the prevention and treatment of acute transplant rejection. It is often used in combination with other immunosuppressive drugs to enhance its effectiveness.

Side effects

Common side effects of muromonab-CD3 include fever, chills, nausea, vomiting, and diarrhea. More serious side effects can include anaphylaxis, a severe allergic reaction that can be life-threatening.

History

Muromonab-CD3 was the first monoclonal antibody to be approved for clinical use in humans. It was approved by the FDA in 1986.

See also

• Monoclonal antibodies
• Transplant rejection
• Immunosuppressive drugs

References

<references />